The spray – which was approved by the FDA in March – has a wholesale acquisition cost of $295 per 28 mg device and costs around $32,400 for a year’s treatment, says ICER.

Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...

The US drugs regulator has approved the sale of a new nasal spray to treat depression ... But critics argue that the spray - sold as Spravato - may have been approved without adequate testing.